Cevostamab

{
  "id": "MLC-T-ONC-012538",
  "term": "Cevostamab",
  "field": "Oncology and biomedicine",
  "definition": "A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.",
  "synonyms": [
    "anti-FCRH5/CD3 TDB BFCR4350A",
    "recombinant anti-FCRH5 x anti-CD3 bi-specific T-cell engager BFCR4350A",
    "FCRH5/CD3 TDB antibody BFCR4350A",
    "FCRH5/CD3 T-cell-dependent bispecific antibody BFCR4350A",
    "anti-FCRH5 x anti-CD3 bi-specific T-cell engager BFCR4350A",
    "anti-FCRH5/CD3 BiTE antibody BFCR4350A",
    "FCRH5/CD3 T Cell dependent bispecific antibody BFCR4350A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cevostamab/"
}